Exonate Limited

Exonate Limited company information, Employees & Contact Information

Explore related pages

Related company profiles:

Exonate is a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases which may lead to vision loss. Our lead asset, EXN407, has the potential to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. The asset met all endpoints and displayed encouraging signals of efficacy in diabetic patients with retinal eye disease (diabetic macular oedema) in a Phase Ib/IIa trial.

Company Details

Employees
15
Founded
-
Address
Wtl Moorfield Road, Duxford,cambridgeshire Cb22 4ps,united Kingdom
Phone
01223 734710
Email
in****@****ate.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Paris.
HQ
Duxford, Cambridgeshire
Looking for a particular Exonate Limited employee's phone or email?

Exonate Limited Questions

News

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema - News-Medical

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema News-Medical

Exonate announces CLEAR-DE trial for EXN407 - Ophthalmology Times Europe

Exonate announces CLEAR-DE trial for EXN407 Ophthalmology Times Europe

Phase Ib/IIa trial of EXN407 eye drops from Exonate demonstrates safety and tolerability - Modern Retina

Phase Ib/IIa trial of EXN407 eye drops from Exonate demonstrates safety and tolerability Modern Retina

Exonate to launch phase 2b trial of EXN407 for diabetic eye disease - PharmaTimes

Exonate to launch phase 2b trial of EXN407 for diabetic eye disease PharmaTimes

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO) - PR Newswire

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO) PR Newswire

Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema - News-Medical

Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema News-Medical

News - First patient dosed with a new eye drop to treat one of the leading causes of blindness - University of Nottingham

News - First patient dosed with a new eye drop to treat one of the leading causes of blindness University of Nottingham

Exonate Receives Wellcome Trust Funding to Develop Eye Drop Treatment for Wet Age-related Macular Degeneration (Wet AMD) - PR Newswire

Exonate Receives Wellcome Trust Funding to Develop Eye Drop Treatment for Wet Age-related Macular Degeneration (Wet AMD) PR Newswire

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease - News-Medical

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease News-Medical

Top Exonate Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant